Related Experiment Video
Updated: Nov 30, 2025
12:59
Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
Published on: September 26, 2013
35.1K
IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases
1Departments of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. hli13@bidmc.harvard.edu.
Clinical Reviews in Allergy & Immunology
|November 13, 2020
Summary
Targeting the interleukin-23/interleukin-17 (IL-23/IL-17) pathway offers new treatments for inflammatory rheumatic diseases. This approach addresses immune system damage to connective tissues and organs, showing significant clinical benefits.
Area of Science:
- Immunology
- Rheumatology
- Molecular Biology
Background:
- Inflammatory rheumatic disorders involve immune system attacks on connective tissues and organs.
- Recent decades have seen significant progress in understanding the cellular and molecular basis of these diseases.
- The discovery of the IL-23/IL-17 axis has been pivotal in advancing therapeutic strategies.
Purpose of the Study:
- To provide an overview of the rationale for targeting the IL-23/IL-17 axis in rheumatic diseases.
- To review the clinical benefits observed from targeting this pathway.
- To discuss the intricate relationship between IL-23 and IL-17, including potential uncoupling in specific conditions.
Main Methods:
- Review of current scientific literature on the IL-23/IL-17 axis in rheumatic diseases.
- Analysis of clinical trial data and therapeutic outcomes.
- Exploration of the molecular interactions between IL-23 and IL-17.
Main Results:
- Targeting the IL-23/IL-17 axis has led to the development of effective new therapies for inflammatory rheumatic conditions.
- Significant clinical benefits have been demonstrated in patients treated by modulating this pathway.
- The interplay between IL-23 and IL-17 is complex and may vary across different rheumatic disease settings.
Conclusions:
- The IL-23/IL-17 axis represents a crucial therapeutic target in managing inflammatory rheumatic diseases.
- Modulating this axis offers substantial clinical advantages and improved patient outcomes.
- Further research is warranted to fully elucidate the IL-23/IL-17 relationship and its therapeutic implications.
Related Concept Videos
01:24T Cell Types and Functions
1.8K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.8K
01:20The JAK-STAT Signaling Pathway
10.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.7K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
321
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
321
01:28Inflammatory Response
15.3K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
15.3K
01:30Inflammatory Response I: Vascular and Cellular
14.6K
The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...
14.6K